Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26931459 | 1.00 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL26931536 | 1.00 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL3349819 | 0.91 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL29155289 | 0.91 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL29155234 | 0.91 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL2676517 | 0.79 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL2675785 | 0.79 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL27689132 | 0.79 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1RPS6KB1 | |
| SCHEMBL378910 | 0.79 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| Hydrochloric Acid SCHEMBL4879041 | 0.78 | OPRM1 (0.54) | OPRM1OPRD1OPRK1OPRL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415356-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | claimed |
| EP-2313391-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-12-26 | — | — | EP | claimed |
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11987597-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-8415356-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415356-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415356-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| EP-2313391-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-12-26 | — | — | EP | disclosed |
| EP-2313391-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-12-26 | — | — | EP | disclosed |
| US-20110130407-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-20110130407-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| WO-2009156339-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156339-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | OPRM1 2376/4885OPRD1 1113/4885OPRK1 985/4885 |
| US-11987597-B2 | Modulators of TNF-α activity | TNF, TNFRSF1A, NFKBIA | OPRM1 2320/4885OPRD1 1236/4885OPRK1 964/4885 |
| US-20110130407-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | OPRM1 572/4885OPRD1 243/4885OPRK1 76/4885 |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | OPRM1 2376/4885OPRD1 1113/4885OPRK1 985/4885 |
| US-12338262-B2 | Modulators of TNF-alpha activity | TNF, TNFRSF1A, NFKBIA | OPRM1 2376/4885OPRD1 1113/4885OPRK1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.